The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s typhoid Vi polysaccharide vaccine market report forecasts the typhoid Vi polysaccharide vaccine market size to grow to $9.20 Billion by 2027, with a CAGR (compound annual growth rate) of more than 16%.

Learn More On The Typhoid Vi Polysaccharide Vaccine Market Report 2023 – https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Typhoid Vi Polysaccharide Vaccine Market Size Forecast
The global typhoid Vi polysaccharide vaccine market is expected to grow from $4.23 billion in 2022 to $4.96 billion in 2023 at a compound annual growth rate (CAGR) of 17.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The typhoid Vi polysaccharide vaccine market is expected to grow to $9.20 billion in 2027 at a CAGR of 16.7%.

Asia-Pacific held the largest typhoid Vi polysaccharide vaccine market share.

Key Typhoid Vi Polysaccharide Vaccine Market Driver ­– Rise In The Typhoid Prevalence
For instance, in March 2021, according to a report shared by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, infections with Salmonella Typhi were believed to affect 5,700 Americans annually, with 620 of these likely to require hospitalization. Typhoid fever mostly causes between 11 and 21 million cases worldwide every year, along with 200,000 fatalities. Therefore, the rising typhoid prevalence is driving the growth of the typhoid Vi polysaccharide vaccine market.

Request for A Sample Of The Global Typhoid Vi Polysaccharide Vaccine Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Key Typhoid Vi Polysaccharide Vaccine Market Trend – Strategic Partnerships
Major companies operating in the typhoid Vi polysaccharide vaccine market are entering into partnerships to strengthen their position in the typhoid Vi polysaccharide market. For instance, in July 2022, The International Vaccine Institute, a South Korea-based international organization focused on infectious diseases of global health importance such as cholera, typhoid, shigella, and salmonella, partnered with Moderna, a US-based biopharmaceutical company. This partnership led to the world’s first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine. Further, in December 2020, Biological E, an India-based biotechnology and biopharmaceutical company, collaborated with the GSK Vaccines Institute for Global Health (GVGH), a UK-based research and development center operating in the typhoid Vi polysaccharide vaccine. This collaboration is for the development of a typhoid conjugate vaccine (TCV).

Typhoid Vi Polysaccharide Vaccine Market Segment
1) By Type: Child, Adult
2) By Route of Administration: Oral, Parenteral
3) By Application: Government Institutions, Private Sector, Other Applications

Typhoid Vi Polysaccharide Vaccine Market Major Players and Strategies
Major players in the typhoid Vi polysaccharide vaccine market are Sanofi Pasteur SA, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, EMERGENT, PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, and Mylan N.V.

The Typhoid Vi Polysaccharide Vaccine Global Market Report 2023 covers regional data on typhoid Vi polysaccharide vaccine market size, typhoid Vi polysaccharide vaccine market trends and drivers, opportunities, strategies, and typhoid Vi polysaccharide vaccine market competitor analysis. The countries covered in the typhoid Vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Typhoid Vi polysaccharide vaccine refers to the recommendation of active immunization for people aged two and up, concerning the prevention of typhoid fever caused by Salmonella typhi.

View More Reports Related To The Typhoid Vi Polysaccharide Vaccine Market –
Pediatric Vaccine Global Market Report 2023
Veterinary Vaccines Global Market Report 2023
Companion Animal Veterinary Vaccines Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: